IQVIA Holdings Inc. (NYSE:IQV) Shares Bought by Nichols & Pratt Advisers LLP MA

Nichols & Pratt Advisers LLP MA grew its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 95,018 shares of the medical research company’s stock after acquiring an additional 4,147 shares during the quarter. IQVIA makes up approximately 1.6% of Nichols & Pratt Advisers LLP MA’s holdings, making the stock its 24th largest position. Nichols & Pratt Advisers LLP MA owned 0.05% of IQVIA worth $21,985,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Lazard Asset Management LLC grew its stake in IQVIA by 2.9% during the 3rd quarter. Lazard Asset Management LLC now owns 2,889,263 shares of the medical research company’s stock worth $568,460,000 after buying an additional 80,189 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. lifted its holdings in shares of IQVIA by 3.4% in the third quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,325,198 shares of the medical research company’s stock valued at $457,483,000 after buying an additional 77,422 shares during the period. Wellington Management Group LLP lifted its holdings in shares of IQVIA by 1.0% in the third quarter. Wellington Management Group LLP now owns 1,816,266 shares of the medical research company’s stock valued at $357,350,000 after buying an additional 17,139 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of IQVIA by 8.7% in the third quarter. JPMorgan Chase & Co. now owns 1,781,283 shares of the medical research company’s stock valued at $350,467,000 after buying an additional 142,707 shares during the period. Finally, Northern Trust Corp lifted its holdings in shares of IQVIA by 1.8% in the third quarter. Northern Trust Corp now owns 1,737,315 shares of the medical research company’s stock valued at $341,817,000 after buying an additional 31,413 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 1.4 %

Shares of NYSE:IQV traded up $3.19 during midday trading on Friday, reaching $232.39. The company had a trading volume of 416,592 shares, compared to its average volume of 954,596. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The business’s 50 day moving average price is $242.48 and its 200 day moving average price is $225.08. The stock has a market cap of $42.34 billion, a PE ratio of 31.31, a P/E/G ratio of 2.16 and a beta of 1.52. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. IQVIA’s quarterly revenue was up 3.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.54 earnings per share. Research analysts forecast that IQVIA Holdings Inc. will post 10.12 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Eric Sherbet sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now directly owns 20,836 shares in the company, valued at $5,031,894. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the sale, the insider now directly owns 796,752 shares in the company, valued at $199,610,278.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Eric Sherbet sold 1,000 shares of the stock in a transaction on Friday, February 16th. The shares were sold at an average price of $241.50, for a total value of $241,500.00. Following the completion of the sale, the insider now owns 20,836 shares of the company’s stock, valued at $5,031,894. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock valued at $10,331,003 over the last 90 days. 1.60% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on IQV shares. Truist Financial reduced their target price on IQVIA from $297.00 to $292.00 and set a “buy” rating for the company in a report on Friday, May 3rd. SVB Leerink began coverage on IQVIA in a research report on Monday, February 26th. They issued an “outperform” rating and a $290.00 target price on the stock. BTIG Research initiated coverage on IQVIA in a report on Tuesday, February 13th. They set a “buy” rating and a $285.00 price objective on the stock. UBS Group increased their target price on IQVIA from $240.00 to $300.00 and gave the company a “buy” rating in a research note on Thursday, February 15th. Finally, Robert W. Baird reduced their price objective on IQVIA from $254.00 to $245.00 and set a “neutral” rating for the company in a research report on Friday, May 3rd. Three equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $257.57.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.